Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nalbuphine Hydrochloride

FDA-approved product (solution, intramuscular, intravenous, subcutaneous), marketed as Nalbuphine, Nalbuphine Hydrochloride, Nubain.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Nalbuphine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Pain

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Morphinan derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nalbuphine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nalbuphine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

    NCT02143648 · start 2014-06

    Registered record
    Registry ID
    NCT02143648
    Conditions
    Uremic Pruritus; Pruritus
    Interventions
    nalbuphine HCl ER tablets 60 mg BID; nalbuphine HCl ER tablets 120mg BID; Placebo tablets BID
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-06
    Completion
    2015-07
    Enrolment
    373

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUremic Pruritus; Pruritus
    Interventionnalbuphine HCl ER tablets 60 mg BID; nalbuphine HCl ER tablets 120mg BID; Placebo tablets BID
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Diclofenac Premedication, as the Effect of Preemptive Analgesia After Post-thoracotomy Chest and Shoulder Pain

    NCT02445599 · start 2014-04

    Registered record
    Registry ID
    NCT02445599
    Conditions
    Pain; Inadequate or Impaired Respiratory Function
    Interventions
    Diclofenac; Midazolam; Atropine; bucain + fentanyl; Nalbuphine; Diclofenac; Metamizole-sodium; Tramadol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-04
    Completion
    2016-04
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain; Inadequate or Impaired Respiratory Function
    InterventionDiclofenac; Midazolam; Atropine; bucain + fentanyl +4 more
    PhasePhase 4
    Registry statusCompleted

  • Study of PHN131 in Patients After Surgery

    NCT02193620 · start 2013-04-30

    Registered record
    Registry ID
    NCT02193620
    Conditions
    Analgesia Disorder
    Interventions
    PHN131 soft capsule with Nalbuphine HCl 60 mg/cap; Placebo soft capsules; Diclofenac
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2013-04-30
    Completion
    2019-02-13
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnalgesia Disorder
    InterventionPHN131 soft capsule with Nalbuphine HCl 60 mg/cap; Placebo soft capsules; Diclofenac
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Herb Drug Interaction of Traditional Chinese Herb and Commonly Used Drugs

    NCT00923000 · start 2008-12

    Registered record
    Registry ID
    NCT00923000
    Conditions
    Healthy
    Interventions
    Nalbuphine; Morphine; Morphine with Long dan xie gan tang; Nalbuphine with Long dan xie gan tang; Nubian with Long dan xie gan tang
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2008-12
    Completion
    2009-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNalbuphine; Morphine; Morphine with Long dan xie gan tang; Nalbuphine with Long dan xie gan tang +1 more
    PhasePhase 1
    Registry statusUnknown

  • Nalbuphine for the Treatment of Opioid Induced Pruritus in Children

    NCT00323154 · start 2004-03

    Registered record
    Registry ID
    NCT00323154
    Conditions
    Pruritis
    Interventions
    Nalbuphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-03
    Completion
    2004-12
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPruritis
    InterventionNalbuphine
    PhasePhase 3
    Registry statusCompleted